Lawrenceville, NJ, United States of America

Mark E Salvati

This inventor holds 34 USPTO granted patents and 4 published patent applications and 5 EPO patents, primarily in CETP Inhibitors. Top assignees: Bristol-Myers Squibb Compnay, American Cyanamid Company. Active years: 2000-2015.

USPTO Granted Patents = 34 (Patent Applications = 4)

% Patents Active = 88.2

EPO Patents = 5 (Patent Applications = 1)

Average Co-Inventor Count = 4.9

ph-index = 8

Forward Citations = 306(Granted Patents)

Location History:

Lawrencevile, NJ (US) (2006)
Lawrenceville, NJ (US) (2000 - 2014)
Pennington, NJ (US) (2008 - 2015)

Company Filing History:

32 out of 3,735

Bristol-Myers Squibb Compnay

patents

2 out of 3,580

American Cyanamid Company

patents

Years Active: 2000-2015

Loading Chart...

Areas of Expertise:

CETP Inhibitors

Nuclear Hormone Receptor

Androgen Receptor

Fused Heterocyclic Compounds

Proliferative Disorders

3-Aminopyrazole

Crystallographic Structure

Bicyclic Modulators

Atherosclerosis

Cardiovascular Diseases

Antiangiogenic Activity

34 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9102599 - N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases (2015-08-11),

2. 8642576 - Heterocyclic CETP inhibitors (2014-02-04),

3. 8404896 - N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases (2013-03-26),

4. 8304403 - Heterocyclic CETP inhibitors (2012-11-06),

5. 7888376 - Heterocyclic CETP inhibitors (2011-02-15),

6. 7790770 - Heterocyclic CETP inhibitors (2010-09-07),

7. 7776859 - Hexahydroimidazopyrazin-3-one compounds useful as modulators of androgen receptor function (2010-08-17),

8. 7655689 - Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function (2010-02-02),

9. 7655688 - Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function (2010-02-02),

10. 7550458 - Tricycloundecane compounds useful as modulators of nuclear hormone receptor function (2009-06-23),

11. 7517904 - Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function (2009-04-14),

12. 7470797 - Fused heterocyclic imido and amido compounds (2008-12-30),

13. 7468439 - Alkylene bridged sultam compounds useful as modulators of nuclear hormone receptor function (2008-12-23),

14. 7432267 - Fused cyclic modulators of nuclear hormone receptor function (2008-10-07),

15. 7342034 - Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function (2008-03-11),

Title: The Inventor Mark E Salvati: Pioneering Innovations in Lawrenceville

Introduction: Mark E Salvati is a distinguished inventor based in Lawrenceville, NJ, known for his groundbreaking contributions to various fields.

Latest Patents: Mark E Salvati holds several patents in the areas of technology, healthcare, and consumer products, showcasing his versatility and ingenuity.

Career Highlights: With a career spanning over two decades, Mark E Salvati has consistently pushed the boundaries of innovation, leading to numerous successful inventions that have made a significant impact.

Collaborations: Throughout his career, Mark E Salvati has collaborated with leading companies, research institutions, and universities to bring his ideas to life, demonstrating his ability to work effectively in multidisciplinary teams.

Conclusion: Mark E Salvati's passion for innovation and his dedication to creating solutions for real-world problems make him a standout figure in the world of inventors.